<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119338">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903070</url>
  </required_header>
  <id_info>
    <org_study_id>00/0594-LINARI</org_study_id>
    <nct_id>NCT01903070</nct_id>
  </id_info>
  <brief_title>Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment</brief_title>
  <official_title>EFFECTS OF LINAGLIPTIN ON ACTIVE GLP-1 CONCENTRATIONS IN SUBJECTS WITH RENAL IMPAIRMENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Profil Institut für Stoffwechselforschung GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Profil Institut für Stoffwechselforschung GmbH</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a bi-centric, prospective, open study comparing the effects of linagliptin on active
      GLP-1 concentrations in subjects with renal impairment compared to subjects with normal
      renal function.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ΔAUCGLP-1-OGTT(0-240)</measure>
    <time_frame>Glucose tolerance test following 7 days of therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>ΔAUCGLP-1-OGTT(0-240) Change in active GLP-1 concentrations after oral glucose ingestion after linagliptin Treatment compared between Groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Linagliptin in TD2 subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in TD2 subjects with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin in TD2 subjects with impaired renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in TD2 subjects with impaired renal function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <arm_group_label>Linagliptin in TD2 subjects</arm_group_label>
    <arm_group_label>Linagliptin in TD2 subjects with impaired renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have Type 2 diabetes mellitus based on the disease diagnostic criteria (WHO)
             classification

        Exclusion Criteria:

          -  Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or
             secondary forms of diabetes such as due to pancreatitis.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christoph Kapitza, MD</last_name>
    <phone>+4921314018</phone>
    <phone_ext>157</phone_ext>
    <email>christoph.kapitza@profil.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <state>NRW</state>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Beer</last_name>
      <phone>+4921314018</phone>
      <phone_ext>145</phone_ext>
      <email>regulatory@profil.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 6, 2014</lastchanged_date>
  <firstreceived_date>July 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>BI 1356</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
